mbiomics GmbH
mbiomics GmbH designs and develops complex Live Biotherapeutics to redefine therapeutics by decoding the microbiome.
Classification
Profile
Funding
Fundraising & market
Designs and develops complex Live Biotherapeutic Products (LBPs) to decode the microbiome and redefine therapeutics.
Pharmaceutical and biotech companies seeking microbiome-based drug development partners.
Likely licensing or partnership deals for developed LBPs, though specific pricing is not detailed.
Direct B2B engagement via corporate website and professional contact channels.
Information insufficient.
High R&D costs associated with designing and developing complex biological therapeutics.
Proprietary microbiome decoding technology and expertise in Live Biotherapeutic Product development.
Designing and developing complex Live Biotherapeutic Products (LBPs) for therapeutic applications.
Information insufficient.
Competes in the microbiome therapeutics space by offering complex LBP development capabilities.
Need to decode the microbiome to discover and develop effective new therapeutics.
Value Proposition ↔ Customer Segments - The analytics platform directly solves pharma’s need for faster, data-driven microbiome drug discove · Channels ↔ Customer Relationships - LinkedIn and conference presence generate leads that are nurtured through dedicated account managers · Key Resources ↔ Revenue Streams - Proprietary platform and IP enable
- The leadership team’s academic credentials and prior biotech experience provide strong scientific credibility [1][2].
- Successful Series A raise from a reputable corporate venture (MIG AG) validates the business model and market potential [2][4].
No investors recorded yet.